# US 2025/0018025 A1 · Agents that engage antigen-presenting cells through dendritic cell asialoglycoprotein receptor (dc-asgpr)

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0018025 A1
- Document ID: US20250018025A1
- Status: Published application
- Kind: A1
- Application number: 18/670,211
- Filed: 2024-05-21
- Published: 2025-01-16
- Earliest claimed: 2007-02-02
- Assignees: Baylor Research Institute
- Applicants: Baylor Research Institute
- Inventors: SangKon OH; Dapeng LI; Jacques Banchereau; Gerard Zurawski; Sandra Zurawski
- Web page: https://patentgrep.com/patent/US20250018025A1

## CPC

- A61K 39/145: Orthomyxoviridae, e.g. influenza virus
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61K 51/1027: {against receptors, cell-surface antigens or cell-surface determinants}
- A61P 31/04: Antibacterial agents
- A61P 31/10: Antimycotics
- A61P 31/12: Antivirals
- A61P 33/00: Antiparasitic agents
- A61P 33/02: Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/04: Immunostimulants
- C07K 14/005: from viruses
- C07K 14/195: from bacteria
- C07K 14/37: from fungi
- C07K 14/405: from algae
- C07K 14/435: from animals; from humans
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- C12N 5/0639: {Dendritic cells, e.g. Langherhans cells in the epidermis}
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 2039/5154: {Antigen presenting cells [APCs], e.g. dendritic cells or macrophages}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/74: Inducing cell proliferation
- C07K 2317/75: Agonist effect on antigen
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C12N 2760/16122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2760/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention includes compositions and methods for making and using anti DC-ASGPR antibodies that can, e.g., activate DCs and other cells.

## Claims

### Claim at position 1

1-13. (canceled)

### Claim 14

An anti-DC-ASGPR immunoglobulin or fragment thereof having an autoantigen attached to the immunoglobulin, wherein the immunoglobulin or fragment comprises an immunoglobulin variable heavy chain region from an immunoglobulin heavy chain having the amino acid sequence of SEQ ID NO: 5, 7, 9, or 11.

### Claim 15 (depends on 14)

The immunoglobulin or fragment of claim 14, wherein the antigen is a fusion protein with the immunoglobulin.

### Claim 16

(canceled)

### Claim 17 (depends on 14)

The immunoglobulin or fragment of claim 14, wherein the immunoglobulin is bound to one half of a cohesin/dockerin domain.

### Claim 18 (depends on 17)

The immunoglobulin or fragment of claim 17, further comprising a complementary cohesin or dockerin domain capable of forming a cohesin/dockerin binding pair.

### Claim 19 (depends on 17)

The immunoglobulin or fragment of claim 17, further comprising a complementary half of the cohesin-dockerin binding pair that is a fusion protein with an antigen.

### Claim 20 (depends on 14)

The immunoglobulin or fragment of claim 14, wherein the immunoglobulin or fragment comprises a full length antibody, an antibody variable region domain, a Fab fragment, a Fab′ fragment, a F(ab)2 fragment, and Fv fragment, an Fabc fragment, and/or a Fab fragment with portions of the Fc domain.

### Claim at position 9

21-29. (canceled)

### Claim 30 (depends on 14)

A vaccine comprising the immunoglobulin or fragment of claim 14.

### Claim 31 (depends on 14)

The immunoglobulin or fragment of claim 14, wherein the autoantigen is Smith protein, RNP ribonucleoprotein, SS-A protein, SS-B protein, acetylcholine receptor, luteinizing hormone, follicular stimulating hormone, testosterone, growth hormone, prolactin, glutamic acid decarboxylase 65 (GAD 65), myelin basic protein, myelin proteolipid protein, thyroglobulin, or thyroid stimulating hormone (TSH) receptor.

### Claim 32 (depends on 31)

The immunoglobulin or fragment of claim 31, wherein the antigen is myelin basic protein.

### Claim 33 (depends on 14)

The immunoglobulin or fragment of claim 14, wherein the antibody or fragment thereof comprises a variable light chain region from a light chain having the amino acid sequence of SEQ ID NO: 6, 8, 10, or 12

### Claim 34 (depends on 33)

The immunoglobulin or fragment of claim 33, wherein the immunoglobulin comprises a variable heavy chain region from an immunoglobulin heavy chain having the amino acid sequence of SEQ ID NO:5 and a variable light chain region from an immunoglobulin light chain having the amino acid sequence of SEQ ID NO:6.

### Claim 35 (depends on 33)

The immunoglobulin or fragment of claim 33, wherein the immunoglobulin comprises a variable heavy chain region from an immunoglobulin heavy chain having the amino acid sequence of SEQ ID NO:7 and a variable light chain region from an immunoglobulin light chain having the amino acid sequence of SEQ ID NO:8.

### Claim 36 (depends on 33)

The immunoglobulin or fragment of claim 33, wherein the immunoglobulin comprises a variable heavy chain region from an immunoglobulin heavy chain having the amino acid sequence of SEQ ID NO:9 and a variable light chain region from an immunoglobulin light chain having the amino acid sequence of SEQ ID NO:10.

### Claim 37 (depends on 33)

The immunoglobulin or fragment of claim 33, wherein the immunoglobulin comprises a variable heavy chain region from an immunoglobulin heavy chain having the amino acid sequence of SEQ ID NO:11 and a variable light chain region from an immunoglobulin light chain having the amino acid sequence of SEQ ID NO: 12.

### Claim 38 (depends on 14)

The immunoglobulin of claim 14, wherein the autoantigen comprises an autoantigen involved in diabetes, diabetes mellitus, arthritis, multiple sclerosis, myasthenia gravis, systemic lupus erythematosis, autoimmune thyroiditis, dermatitis, psoriasis, Sjogren's Syndrome, alopecia areata, allergic responses due to arthropod bite reactions, Crohn's disease, aphthous ulcer, iritis, conjunctivitis, keratoconjunctivitis, ulcerative colitis, asthma, allergic asthma, cutaneous lupus erythematosus, scleroderma, vaginitis, proctitis, drug eruptions, leprosy reversal reactions, erythema nodosum leprosum, autoimmune uveitis, allergic encephalomyelitis, acute necrotizing hemorrhagic encephalopathy, idiopathic bilateral progressive sensorineural hearing loss, aplastic anemia, pure red cell anemia, idiopathic thrombocytopenia, polychondritis, Wegener's granulomatosis, chronic active hepatitis, Stevens-Johnson syndrome, idiopathic sprue, lichen planus, Crohn's disease, Graves ophthalmopathy, sarcoidosis, primary biliary cirrhosis, uveitis posterior, and interstitial lung fibrosis.

### Claim 39 (depends on 38)

The immunoglobulin of claim 38, wherein the autoantigen comprises an autoantigen associated with multiple sclerosis.

### Claim 40 (depends on 38)

The immunoglobulin of claim 38, wherein the autoantigen comprises an autoantigen associated with systemic lupus erythematosus (SLE).

### Claim 41 (depends on 38)

The immunoglobulin of claim 38, wherein the autoantigen comprises an autoantigen associated with myasthenia gravis (MG).

### Claim 42

A method of delivering an antigen to an antigen presenting cell, comprising administering to the antigen presenting cell an effective amount of a composition comprising a recombinant fusion protein, said fusion protein comprising an anti-human dendritic cell asialoglycoprotein receptor (ASGPR) antibody or an antigen binding fragment thereof and one or more autoimmune antigens, wherein the antibody or fragment thereof comprises (a) an immunoglobulin heavy chain selected from the group consisting of SEQ ID NO: 5, 7, 9, and 11; and (b) an immunoglobulin light chain selected from the group consisting of SEQ ID NO: 6, 8, 10, and 12.

### Claim 43

A method of decreasing an antibody-mediated immune response to an autoantigen in a subject, comprising the step of administering to the subject an effective amount of a composition comprising a recombinant fusion protein, said fusion protein comprising an anti-human dendritic cell asialoglycoprotein receptor (ASGPR) antibody or an antigen binding fragment thereof and one or more autoimmune antigens, wherein the antibody or fragment thereof comprises (a) an immunoglobulin heavy chain selected from the group consisting of SEQ ID NO: 5, 7, 9, and 11; and (b) an immunoglobulin light chain selected from the group consisting of SEQ ID NO: 6, 8, 10, and 12.
